Viking Therapeutics (VKTX) Gets a Buy Rating from Stifel Nicolaus

By Austin Angelo

In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Viking Therapeutics (VKTXResearch Report), with a price target of $14.00. The company’s shares closed last Thursday at $5.76.

According to TipRanks.com, Archila is a 3-star analyst with an average return of 1.4% and a 43.3% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $14.80.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.93 and a one-year low of $3.26. Currently, Viking Therapeutics has an average volume of 1.49M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.